Annual Report And Group Financial Statements

Overview

The report describes a strategic refocus on VISITECT® CD4, Allersys® and Food intolerance after a challenging year. Group revenue declined 5% to £13.6 million, while the company closed its Germany and Pune operations and divested its legacy infectious disease business. Operational progress included CE marking for VISITECT® CD4 and 53 allergens for the IDS instrument, alongside a global IDS distribution agreement. The report also notes continuing development and commercialisation work for the CD4 test range.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2018
Period: Ends 31 March 2018
Language: English
Pages
File size
Restatement: Disclosed

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services